Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Prince, H. M.
Right arrow Articles by Keating, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prince, H. M.
Right arrow Articles by Keating, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:1043-1049, 1996
© 1996 European Society for Medical Oncology

research-article

Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma

H. M. Prince, M. Crump, K. Imrie, A. K. Stewart, C. Girouard, J. M. Brandwein, K. Carstairs, D. Pantalony, G. Scott, S. Sutcliffe, D. M. C. Sutton, R. Tsang and A. Keating

University of Toronto Autologous Blood and Marrow Transplant Program, The Toronto Hospital Toronto, Ontario, Canada

Correspondence to: Dr. M. Crump The Toronto Hospital 200 Elizabeth St. mlw 2-018 Toronto, Ontario Canada M5G 2C4

BACKGROUND:: Patients with Hodgkin's disease (HD) and intermediate or high-grade non-Hodgkin's lymphoma (NHL) who fail to achieve a complete remission (CR) with standard induction therapy have a poor prognosis with conventional-dose salvage therapy alone. We examined the role of subsequent intensive therapy and autologous bone marrow transplantation (ABMT) in patients who demonstrated a response to conventional-dose salvage therapy.

PATIENTS AND METHODS:: Sixty-six patients with either HD (n = 30) or NHL (n = 36) underwent intensive therapy with etoposide (60 mg/kg), intravenous melphalan (160–180 mg/m2) followed by infusion of unpurged autologous bone marrow and/or blood cells. All patients had advanced stage or bulky disease at diagnosis and failed to achieve a CR after an anthracycline-containing front-line chemotherapy regimen (NHL) or ABVD or equivalent regimen (HD). Patients who achieved a CR after involved-field radiotherapy were excluded. All patients demonstrated sensitivity to conventionaldose salvage treatment before advancing to intensive therapy and ABMT.

RESULTS:: The CR, partial response (PR) and overall response rate (RR) following ABMT for HD patients was 48%, 17% and 65%, respectively. At a median follow-up of 35 months, the predicted three-year overall survival (OS) is 51% (95% CI: 44%–60%) and event-free survival (EFS) is 34% (95% CI: 26%–54%). For patients with NHL, the CR, PR and RR were 68%, 9% and 77%, respectively. At a median follow-up of 28 months, the predicted three-year OS is 51% (95% CI: 35%–66%) and EFS is 39%(95% CI: 21%–57%).

CONCLUSIONS:: Intensive therapy with etoposide and melphalan followed by ABMT results in prolonged survival in selected patients with lymphoma who fail to achieve a complete remission to front-line chemotherapy. Based on our previous studies of outcome to conventionaldose salvage chemotherapy, we estimate that of all patients failing induction therapy, 28% with HD and 15% with NHL will be eventfree at three years after ABMT.

induction failure, Hodglun's disease, non-Hodgkin's lymphoma, refractory lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
A. Santoro, M. Magagnoli, M. Spina, G. Pinotti, L. Siracusano, M. Michieli, A. Nozza, B. Sarina, E. Morenghi, L. Castagna, et al.
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
Haematologica, January 1, 2007; 92(1): 35 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Rodriguez, M. D. Caballero, A. Gutierrez, C. Solano, R. Arranz, J. J. Lahuerta, J. Sierra, M. Gandarillas, J. A. Perez-Simon, J. Zuazu, et al.
Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience
Ann. Onc., October 1, 2004; 15(10): 1504 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology, January 1, 2003; 2003(1): 225 - 247.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Vose, M.-J. Zhang, P. A. Rowlings, H. M. Lazarus, B. J. Bolwell, C. O. Freytes, S. Pavlovsky, A. Keating, B. Yanes, K. van Besien, et al.
Autologous Transplantation for Diffuse Aggressive Non-Hodgkin's Lymphoma in Patients Never Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry
J. Clin. Oncol., January 15, 2001; 19(2): 406 - 413.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Kewalramani, A. D. Zelenetz, E. E. Hedrick, G. B. Donnelly, S. Hunte, A. C. Priovolos, J. Qin, N. C. Lyons, J. Yahalom, S. D. Nimer, et al.
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
Blood, October 1, 2000; 96(7): 2399 - 2404.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. H. M. Lazarus, P. A. Rowlings, M.-J. Zhang, J. M. Vose, J. O. Armitage, P. J. Bierman, J. L. Gajewski, R. P. Gale, A. Keating, J. P. Klein, et al.
Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry
J. Clin. Oncol., February 1, 1999; 17(2): 534 - 534.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.